Development · 7 Oct 2026
2 publishers have reported this development. Each act of reporting is below, cited.
Granules India has submitted a Paragraph IV certification in connection with its Abbreviated New Drug Application for Ruxolitinib Extended-Release Tablets with respect to applicable patents listed with the US Food and Drug Administration.
Granules India Limited announced that it has submitted a Paragraph IV certification in connection with its ANDA for Ruxolitinib Extended-Release Tablets with respect to applicable patents listed in the US Food and Drug Administration’s Orange Book.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.